Fig. 1From: Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL dataTrends in proportion of new user episodes which were SGLT-2i by A country and B overall in 2012–2017 (pre-propensity matching). SGLT-2i sodium–glucose cotransporter-2 inhibitorBack to article page